Please login to the form below

Not currently logged in
Email:
Password:

Roche to buy Anadys for $230m

Roche is to acquire US-based Anadys Pharmaceuticals for $230m, developing the company's hepatitis C capabilities

Roche is to acquire US-based Anadys Pharmaceuticals for $3.70 per share – about $230m in total.

Anadys specialises in the development of oral, small molecule therapeutics for the potential treatment of hepatitis C virus infection.

The deal will see Roche take ownership of the drug candidate setrobuvir (ANA598), which is currently in a phase II study in combination with Roche's (Pegasys) pegylated interferon and (Copegus) ribavirin.

Other products in development include ANA773, which is currently at phase I trial stage for the treatment of hepatitis C as well as other chronic infections and cancer.

Jean-Jacques Garaud, global head of Roche pharmaceutical research and early development, said the acquisition would enhance the company's presence in the treatment of hepatitis C.

He said: "Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon."

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics